Low Incidence of Atrial Fibrillation in Patients with Obstructive HCM Treated with Aficamten: An Analysis from the REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM Trials #OpenAccess @EthanRowin @LaheyHospital https://t.co/RIAMHpahRp

We presented long-term data from #FOREST #HCM on the incidence and impact of atrial fibrillation in patients treated with aficamten in the Cardiomyopathy LBCT session Led by @EthanRowin #ESC2025 #CardioTwitter

Extended Ambulatory ECG Monitoring Enhances Identification of Higher-Risk Ventricular Tachyarrhythmias in Patients with Hypertrophic Cardiomyopathy #OpenAccess @EthanRowin @MartinMaronMD https://t.co/xXU3QzsUBL

Amazing session on #HCM and arrhythmias — from the newer high-risk makers to challenges of VT ablation, role of PFA, and updated exercise guidelines. #EPeeps #HRS2025 #2025pacesetter @EthanRowin

New mavacamten FDA label update Most relevant parts: 1) Initiation strategy remains the same 2) Maintenance phase echo requirement dropped to once every 6 months instead of once every 3 months This will help with patient and staff burden during the maintenance phase. I would

How have HCM mortality rates changed before and after COVID ❓ 1⃣ Prior to COVID, mortality rates declined by ~ half📉 2⃣ After COVID, mortality rates increased by ~30%, partially undoing some of the prior reductions in HCM mortality.📈 Open access📜: https://t.co/FnIeFes37e

Really valuable and novel data presented by Dr. @EthanRowin — Does LV apical aneurysm size matter for SCD risk in #HCM? 🏥 Multicenter data says yes! #ACC25 #CardioTwitter

“Excited to share our latest editorial published in @CircAHA - Our study highlights T1 mapping as a novel marker for heart failure progression in hypertrophic cardiomyopathy (HCM). @EthanRowin @JAHA_AHA @AHAScience

Mavacamten in #nonobstructive #HCM design and baseline characteristics paper is out (ODYSSEY trial) ! Biggest unmet need in HCM is nonobstructive HCM. We look forward to the results. Impressive baseline characteristics with significant burden of disease Sample size caught

Disopyramide appears safe and effective in treating symptomatic outflow obstruction in HCM over extended durations of time (≥5 years). #AHAJournals @danmassera @nyulangone @EthanRowin @LaheyHospital https://t.co/0J0CyfDqFC

Disopyramide for long-term treatment of obstructive #hcm? Check out our work looking at patients treated for ≥5 years at @nyulangone @LaheyHospital with 67% still on drug after ~7 years @EthanRowin @MartinMaronMD https://t.co/TJXLB1T8aU

#cardiotwitter: How do you approach apical aneurysms in hypertrophic #cardiomyopathy? Excited to contribute to the latest @hcmsociety "In the Thick of It" podcast with @EthanRowin #cvHCM

@RickNishimura and Dr. Barry Maron at #HCMSummit8. Great to hear from many experts on HCM. @HCMSummit @SteveOmmen @MartinMaronMD

Extended Ambulatory ECG Monitoring Enhances Identification of Higher-Risk Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy https://t.co/upxcwC7Hbr

🚨 Boston is SOLD OUT!🎟️ Get your VIRTUAL ticket for #HCMSummit8 & join us live Oct 25-27 to learn from leading global #HCM experts, with on-demand access thru April 2025. Don’t miss out! Tickets: https://t.co/0qWKeem7Gz #CardioResearch #HypertrophicCardiomyopathy #CardioTwitter

Our third Industry Product Theater is sponsored by @iRhythmTech & all attendees are invited! Sat, Oct 26 @ 7:15 AM ET w @mmartinezheart @tikuowens @EthanRowin #dannaspears & #barrymaron. Details: https://t.co/CVp5Inm2Df #HCMSummit8 #HCM #CardioTwitter #HypertrophicCardiomyopathy

Percutaneous Left Atrial Appendage Closure for Stroke Prevention in Hypertrophic Cardiomyopathy Patients with Atrial Fibrillation @EthanRowin https://t.co/vPCDrPjDtQ

📯LGE=0 was associated with very low rates of SCD (0.34%/y) and mortality among #HCM. Zero LGE had a strong negative predictive value over 5 yrs from initial #CMR. When do we rescan again⁉️ Glad to share our 📜 @JACCJournals led by @mmartinezheart @MartinMaronMD @EthanRowin

Novel data underscore an essential principle in HCM: genetic testing results do not reliably predict prognosis or dictate management decisions for individual patients. #AHAJournals @BonaventuraJiri @EthanRowin @MTChinMDPhD @MartinMaronMD https://t.co/VdZuy99D7P

Great work by @AmroAglanMD @AymanFathMD1 and team evaluating if LAA closure is effective to prevent strokes in HCM patients with AF